EP Patent

EP4578443A1 — Oral suspensions comprising nintedanib esylate

Assigned to Faran SA · Expires 2025-07-02 · 1y expired

What this patent protects

Oral pharmaceutical suspension comprising nintedanib esylate and a non-aqueous liquid carrier comprising one or more medium-chain fatty acid triglycerides and at least one suspending agent.

USPTO Abstract

Oral pharmaceutical suspension comprising nintedanib esylate and a non-aqueous liquid carrier comprising one or more medium-chain fatty acid triglycerides and at least one suspending agent.

Drugs covered by this patent

Patent Metadata

Patent number
EP4578443A1
Jurisdiction
EP
Classification
—
Expires
2025-07-02
Drug substance claim
No
Drug product claim
No
Assignee
Faran SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.